Acer Therapeutics Inc. (NASDAQ: ACER) is -5.73% lower on its value in year-to-date trading and has touched a low of $1.08 and a high of $7.25 in the current 52-week trading range. The ACER stock was last observed hovering at around $2.47 in the last trading session, with the day’s gains setting it 0.05% off its average median price target of $10.00 for the next 12 months. It is also 74.8% off the consensus price target high of $10.00 offered by 4 analysts, but current levels are 74.8% higher than the price target low of $10.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $2.52, the stock is -0.59% and -3.37% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing 2.02% at the moment leaves the stock -12.75% off its SMA200. ACER registered -39.61% loss for a year compared to 6-month loss of -25.15%. The firm has a 50-day simple moving average (SMA 50) of $2.5564 and a 200-day simple moving average (SMA200) of $2.9542.
The stock witnessed a 5.56% gain in the last 1 month and extending the period to 3 months gives it a -16.55%, and is -2.76% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.97% over the week and 6.46% over the month.
Distance from 52-week low is 133.33% and -65.24% from its 52-week high.
Acer Therapeutics Inc. (ACER) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Acer Therapeutics Inc. (ACER) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.50, where 2 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Acer Therapeutics Inc. is expected to release its quarterly report on 05/19/2021 and quarterly earnings per share for the current quarter are estimated at -$0.41.The EPS is expected to shrink by -17.20% this year.
Acer Therapeutics Inc. (ACER) Top Institutional Holders
36 institutions hold shares in Acer Therapeutics Inc. (ACER), with 3.1M shares held by insiders accounting for 25.21% while institutional investors hold 50.10% of the company’s shares. The shares outstanding are 11.51M, and float is at 9.19M with Short Float at 4.53%. Institutions hold 37.47% of the Float.
The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 0.99 million shares valued at $2.85 million. The investor’s holdings represent 8.06% of the ACER Shares outstanding. As of Sep 29, 2020, the second largest holder is Worth Venture Partners, LLC with 0.25 million shares valued at $0.72 million to account for 2.04% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 0.12 million shares representing 1.00% and valued at over $0.35 million, while Federated Hermes, Inc. holds 0.96% of the shares totaling 0.12 million with a market value of $0.34 million.
Acer Therapeutics Inc. (ACER) Insider Activity
A total of 3 insider transactions have happened at Acer Therapeutics Inc. (ACER) in the last six months, with sales accounting for 0 and purchases happening 3 times. The most recent transaction is an insider purchase by ASELAGE STEVE, the company’s Director. SEC filings show that ASELAGE STEVE bought 45,000 shares of the company’s common stock on Jul 24 at a price of $3.50 per share for a total of $0.16 million. Following the purchase, the insider now owns 63905.0 shares.
Acer Therapeutics Inc. disclosed in a document filed with the SEC on Jul 24 that Joseph Donald (Chief Legal Officer and Secy) bought a total of 14,285 shares of the company’s common stock. The trade occurred on Jul 24 and was made at $3.50 per share for $49998.0. Following the transaction, the insider now directly holds 14285.0 shares of the ACER stock.
Still, SEC filings show that on Jul 24, DUNN JOHN MICHAEL (Director) acquired 21,428 shares at an average price of $3.50 for $74998.0. The insider now directly holds 27,380 shares of Acer Therapeutics Inc. (ACER).
Acer Therapeutics Inc. (ACER): Who are the competitors?
The company’s main competitors (and peers) include Biogen Inc. (BIIB) that is trading -9.10% down over the past 12 months. Fortress Biotech Inc. (FBIO) is 37.53% up on the 1-year trading charts. Short interest in the company’s stock has risen 16.37% from the last report on Nov 12, 2020 to stand at a total of 0.35 million short shares sold with a short interest ratio of 4.35.